Change search
ReferencesLink to record
Permanent link

Direct link
Screening for C3 deficiency in newborns using microarrays.
KTH, School of Biotechnology (BIO), Proteomics (closed 20130101). KTH, Centres, Science for Life Laboratory, SciLifeLab.
Show others and affiliations
2009 (English)In: PloS one, ISSN 1932-6203, Vol. 4, no 4, e5321- p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Dried blood spot samples (DBSS) from newborns are widely used in neonatal screening for selected metabolic diseases and diagnostic possibilities for additional disorders are continuously being evaluated. Primary immunodeficiency disorders comprise a group of more than one hundred diseases, several of which are fatal early in life. Yet, a majority of the patients are not diagnosed due to lack of high-throughput screening methods.

METHODOLOGY/PRINCIPAL FINDINGS: We have previously developed a system using reverse phase protein microarrays for analysis of IgA levels in serum samples. In this study, we extended the applicability of the method to include determination of complement component C3 levels in eluates from DBSS collected at birth. Normal levels of C3 were readily detected in 269 DBSS from healthy newborns, while no C3 was detected in sera and DBSS from C3 deficient patients.

CONCLUSIONS/SIGNIFICANCE: The findings suggest that patients with deficiencies of specific serum proteins can be identified by analysis of DBSS using reverse phase protein microarrays.

Place, publisher, year, edition, pages
2009. Vol. 4, no 4, e5321- p.
National Category
Medical Biotechnology
URN: urn:nbn:se:kth:diva-83827DOI: 10.1371/journal.pone.0005321ISI: 000265514400009PubMedID: 19390687OAI: diva2:499010

QC 20120213

Available from: 2012-02-13 Created: 2012-02-13 Last updated: 2015-05-28Bibliographically approved
In thesis
1. On Generation and Applications of High-Density Protein Microarrays
Open this publication in new window or tab >>On Generation and Applications of High-Density Protein Microarrays
2015 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Affinity proteomics has experienced rapid development over the last two decades and one of the most promising platforms to emerge are the protein microarrays. The combination of affinity reagents and miniaturisation enables assays for simultaneous high throughput and sensitive protein analysis. Due to the combination of these desrable properties, a multitude of protein array platforms for rapid and efficient study of proteomes and protein interactions are in use today. Although the protein microarray field has more than two decades of history to look back on the development of new protein microarray platforms continues to this day and beyond.

In the paper I in this thesis, a microarray of eluates from dried blood spot samples collected from neonates were designed and utilised for detection of complement factor 3 (C3) deficiency. The data acquired from the microarrays platform were compared to C3 levels obtained through enzyme-linked immunosorbant assay (ELISA), and the microarray assay were found to separate the C3 deficient samples from the controls. The conclusion of this investigation was that the microarray platform would be suitable for high-throughput screening of C3 deficiency in neonates. Paper II outlines the work in developing a multiplex platform for validation of affinity reagents. A set of 398 affinity binders, originating from five research groups, were profiled against 432 antigens and representing both polyclonal rabbit antibodies, monoclonal mouse antibodies, and recombinant single-chain variable fragments. Approximately 50% of the binders were found to preferably recognise their intended target while 10% of the binders did not generate any, or low, signals with their respective targets. For paper III, a reverse phase array (RPPA) platform using fluorescence-based detection of IgA deficiency in over 2.000 samples where validated on a label-free detection system and ELISA. The data from the label-free platform and the RPPA were found agree well with each other while data from ELISA did with neither of them. It was found that the label-free platform proved to be well-suited for detection of IgA in serum. Paper IV describes one of the world’s largest protein microarrays containing 21.120 recombinant protein fragments. We describe some of the possible applications of these large-scale arrays, such as binding profiles for the validation of antibodies with 11.520 and 21.120 recombinant proteins, as well as screening for autoimmunity in human serum samples.

Place, publisher, year, edition, pages
Stockholm: KTH Royal Institute of Technology, 2015. ix, 63 p.
TRITA-BIO-Report, ISSN 1654-2312 ; 2015:12
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
urn:nbn:se:kth:diva-168165 (URN)978-91-7595-579-7 (ISBN)
Public defence
2015-06-12, Inghe-salen, Tomtebodavägen 18a, Solna, 10:00 (English)

QC 20150528

Available from: 2015-05-28 Created: 2015-05-27 Last updated: 2016-01-28Bibliographically approved

Open Access in DiVA

fulltext(300 kB)13 downloads
File information
File name FULLTEXT01.pdfFile size 300 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sjöberg, RonaldNilsson, Peter
By organisation
Proteomics (closed 20130101)Science for Life Laboratory, SciLifeLab
Medical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar
Total: 13 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 45 hits
ReferencesLink to record
Permanent link

Direct link